Loading...
Blood biomarkers, particularly plasma phosphorylated tau 217 (p-tau217), have become central to the biological diagnosis of Alzheimer’s disease (AD). However, because prion diseases may present as rapidly progressive dementia mimicking AD, disease-specific biomarkers are needed. Researchers evaluated the diagnostic performance of several plasma AD biomarkers in patients with prion diseases and explored strategies to better differentiate between the two neurodegenerative disorders.
Plasma p-tau217 and p-tau181 were markedly elevated in patients with prion diseases, demonstrating that these markers are not exclusive to AD.
The plasma β-amyloid 42 (Aβ42)/Aβ40 ratio showed only moderate diagnostic accuracy, and glial fibrillary …